Skip to main content

Press releases | January 9, 2023

Fried Frank acted as counsel to Centerview as financial advisor to Albireo (Nasdaq: ALBO), a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases, in its acquisition by French biopharmaceutical company, Ipsen.

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.